Prostaglandin E 2 plays multiple roles both in the physiology and the physiopathology of human brain, which are not completely understood. We have identified in a subset of human glioblastoma multiforme (GBM) tumors, the most common form of adult brain cancer, an increased expression of mPGES-1, the enzyme which catalyses the isomerization of PGH 2 into PGE 2 downstream of cyclooxygenase 2 (COX-2). The sensitivity of primary cultures of GBM to apoptosis was augmented by the overexpression of mPGES-1, whereas the knockdown of its expression by shRNA decreased the apoptotic threshold in vitro and stimulated tumor growth in vivo. Adding extracellular PGE 2 in the culture medium failed to reproduce mPGES-1 effect on the cell viability in vitro. However, the intracellular injection of PGE 2 induced a dose-dependent apoptosis in GBM cultures, which was dependent on the presence of Bax, a pro-apoptotic protein.
Introduction
Cyclooxygenases (COX-1 and COX-2) are the enzymes responsible for the transformation of the arachidonic acid into prostaglandin H 2 (PGH 2 ), which is, in turn, converted into multiple prostanoids by specific enzymes (Cha et al., 2006) . Prostaglandins are lipid mediators secreted and not usually stored, by many cells, either constitutively or in response to specific trauma, stimuli or signaling molecules. In the past decade, the role of COX-2 has been the topic of intense research, as epidemiological studies and clinical trials have indicated that the use of non-steroidal anti-inflammatory drugs (NSAIDS), potent inhibitors of COX-2, could decrease the incidence of certain malignancies such as colorectal, breast, lung and bladder cancers (Wang and DuBois, 2006) . However, severe cardiovascular and cerebral side effects have hampered the further use of specific COX-2 inhibitors. A better knowledge on the importance and the relationships between the many signaling pathways downstream of COX-2 are thus crucial to understand the action of these inhibitors and to develop more efficient strategies on different pathologies (Wang and DuBois, 2006) .
In the brain, the situation of COX-2 appears to be particularly complex (Musiek et al., 2005) as it is constitutively expressed under normal conditions contrary to other tissues and significantly elevated during neurodegenerative diseases (Herrmann et al., 2005) and tumorigenesis (Williams et al., 2000; Gupta and DuBois, 2001; Shono et al., 2001; Castellone et al., 2005) . The expression of COX-2 is regulated by physiological activity at the synaptic level and is strongly induced by the excessive activation of N-methyl-D-aspartate (NMDA) receptors and thus in glutamate excitotoxicity during cerebral ischemia. Of note, COX-2-deficient mice are less susceptible to both focal and global brain injury while they exhibit profound dysfunction of the kidney and the gastric tractus. The importance of COX-2 in the inflammatory process and its subsequent deleterious effects have been involved in both the neurodegenerative processes and the tumoral progression. However, data in the literature suggest that COX-2 could exert an antiapoptotic activity and this feature could be central for its tumorigenic property. These results suggest that COX-2 and possibly PGE 2 display distinct tissuespecific functions and/or physio-pathological situations.
The mechanism by which COX-2 could differently influence cell death is poorly defined but may be linked to the production of PGE 2 and not the production of reactive oxygen species (Manabe et al., 2004) . Indeed, several results have suggested that PGE 2 could trigger different and opposed responses depending on its concentration. For example, in the central nervous, PGE 2 can either induce apoptosis or be neuroprotective depending on its concentration (Takadera et al., 2002; McCullough et al., 2004; Chen and Bazan, 2005; ) . The opposite functions could be related to the interaction of PGE 2 with different specific plasma membrane receptors called EP receptors. Kawano and co-workers (Kawano et al., 2006) recently showed that PGE 2 induces neurotoxicity through one of its specific plasma membrane receptors (i.e. EP1), whereas other receptors (namely EP2, EP3 and EP4) are neuroprotective (McCullough et al., 2004) . This implies that PGE 2 can exert opposite effects on neurons depending on the cellular or the molecular context.
It has been suggested that PGE 2 may modulate tumoral growth by several means (i.e. apoptosis, metastasis, multidrug resistance, angiogenesis, and modulation of anti-tumoral immune response) in several types of tumors (Wang and DuBois, 2006) . In brain tumors, a correlation between the overexpression of COX-2 and the grade of the tumor has been reported (Shono et al., 2001; Hara and Okayasu, 2004) . However, no statistical correlation between COX-2 expression and survival has been found in glioblastoma multiforme (GBM), the most aggressive brain tumors in adult (Buccoliero et al., 2006) . Microsomal prostaglandin E 2 synthase-1 (mPGES-1) is the rate limiting enzyme responsible for the synthesis of PGE 2 downstream of COX-2 , but to our knowledge, the expression of this enzyme has not been studied in human GBM patients. Thus, because of the fundamental role played by prostaglandin E 2 in the brain and its supposed role in tumoral growth, we have studied the expression of the two enzymes in the biosynthesis of PGE 2, COX-2 and mPGES-1, in a retrospective clinical analysis realized on 60 patients with GBM.
Results
The expression of mPGES-1 is correlated with a longer survival in GBM patients We have investigated the role of this enzyme and its product PGE 2 on gliomas growth and cell death on 60 patients treated at the Department of Neurosurgery of the Hospital of Nantes over the years [1996] [1997] [1998] [1999] [2000] [2001] (Supplementary data 1). The expression of COX-2 and mPGES-1 was estimated by western blot in the tumoral sample and quantified as described in Materials and methods. The amount of COX-2 appeared to be quite homogenous in the GBM analysed (Figure 1a , left). By contrast, two subpopulations could be clearly observed according to mPGES-1 expression, one of the enzymes implicated in the synthesis of PGE 2 downstream of COX-2 (Kudo and Murakami, 2005) (Figure 1a , middle). We observed a correlation between the expression of mPGES-1 and the amount of PGE 2 measured in 10 tumors (Figure 1a , right). This result was expected as mPGES-1 appears to be the rate-limiting enzyme in PGE 2 synthesis in many tissues. The mPGES-1 immunostaining was restricted to endothelial cells in the peritumoral tissue, whereas all tumoral cells were positively stained (Figure 1b) . The correlation between mPGES-1 expression in the tumor and the average survival of GBM patients was assayed by a KaplanMeier plot using the western blots quantification of the enzyme as the variable. As shown in Figure 1c , mPGES-1 high expression in GBM was found to be predictive of a longer survival (PGES H 23.31 months vs PGES L 12.41 months; P ¼ 0.0254, unpaired two-tailed t-test).
We noticed that among other variables (Supplementary data 2), there was a significant correlation between mPGES-1 expression in tumors and DEVDase activity in the tumoral extracts (Figure 1d ) (Po0.0001, Fisher's exact test), suggesting a positive correlation between the expression of mPGES-1 and apoptosis.
mPGES-1 is apoptogenic in GBM primary cultures
We were able to generate several primary cultures from the GBM with high and low amount of PGES (respectively PGES-H and PGES-L) defined in Figure 1a . The expression of mPGES-1 was not altered in the primary cultures (Figure 2a ), suggesting that expression of mPGES-1 was intrinsic to the tumor and not induced by external factors such as inflammatory processes. To assess the relevance of this in vivo correlation between tumoral expression of mPGES-1 and apoptosis, we induced stable mPGES-1 overexpression in PGES H and PGES L primary cultures. Apoptosis was induced by staurosporine (150 nM for 12 h) and its induction estimated by the quantification of the DEVDase activity as described previously (Cartron et al., 2003b) . As shown in Figure 2a , the overexpression of mPGES-1 induced an increase in both spontaneous and STS-induced apoptosis. The primary cultures from GBM PGES L and GBM PGES H as well as stable transfectants for mPGES-1 were injected in the flank of immunodeficient nude mice. As shown in Figure 2b , PGES L tumors grew faster than the PGES H tumors. When PGES L GBM were transfected by a mPGES-1 plasmid, the tumoral growth was reduced to a level similar to that of GBM PGES H tumors. The downregulation of the expression of mPGES-1 was achieved by the transfection of shRNA in PGES L primary cultures. The efficiency of mPGES-1 knockdown and the subsequent decrease in PGE 2 synthesis were verified by FACS analysis and by EIA assay respectively (Supplementary data 3). shRNA-transfected cells were treated by staurosporine and apoptosis estimated by the quantification of DEVDase activity. Figure 2c shows that the mPGES-1 knockdown renders the cells resistant to apoptosis. By contrast, COX-2 downregulation increased the sensitivity of the cells to staurosporine (Figure 2c ). These results suggest that COX-2 and mPGES-1 exert opposite effects on apoptosis.
These shRNA GBM cells were injected subcutaneously to nude mice, each mouse receiving control cells (treated with control shRNA) injection in the controlateral flank ( Figure 2d ). mPGES-1 knockdown drastically increased the growth of GBM in nude mice ( Figure 2d) ; similar results were obtained with two different shRNA (data not shown).
Intracellular PGE 2 is a potent inducer of apoptosis
We next examined the implication of PGE 2 , mPGES-1 product, in the GBM cells apoptosis. Transfection of primary culture with mPGES-1 induces an increase in the biosynthesis of PGE 2 ( Figure 3a) . Treatment of Bax-expressing GBM (BeGBM) primary cultures with extracellular PGE 2 neither induced cell death nor sensitized the cells to apoptosis ( Figure 3b ). As PGE 2 was also observed in the cellular compartment of GBM (Supplementary data 3), we investigated the role of intracellular PGE 2 in apoptosis. Most cells exhibit a very efficient exclusion mechanism of PGE 2 which has been shown to be partially mediated by the multiple drug resistance protein MRP4 and to be inhibited by ketoprofen (Reid et al., 2003) . PGE 2 is rapidly inactivated in vivo by the action of 15-hydroxy prostaglandin dehydrogenase (15-hydroxy PGDH) which is selectively inhibited with CAY10397. This inhibition prolongs the lifetime and activity of endogenously produced prostaglandins both in cell culture and in vivo (Berry et al., 1983) . It seems that PGE 2 catabolism by 15-PGDH does not occur in the brain after birth; PGE2 is then secreted through the bloodbrain barrier (Krunic et al., 2000) . PGE 2 and its derivatives are usually known to signal through the activation of various transcriptional pathways following the binding of receptors, including the EP receptors and the peroxisome proliferator-activated receptors (PPAR) (Breyer et al., 2001) . To increase the intracellular concentration of PGE 2 we treated GBM primary cultures by a combination of drugs, including actinomycin D to prevent the transcription induced by PGE 2 , CAY10397 to inhibit its metabolic inactivation and ketoprofen to inhibit PGE 2 exportation (Figure 3c ). In the presence of this regimen, the spontaneous apoptosis was increased in a PGE 2 -dependent manner (Figure 3d ), whereas PGE 2 alone induced no cell death (Figure 3b ). In fibroblasts, the addition of interleukin 1b (IL1-b) induces COX-2 and mPGES-1 transcription (YucelLindberg et al., 2006) . When the non-cancerous cell line rat fibroblast-1 was treated with a combination of both IL1-b and the drugs used in Figure 3d (Figure 3b) ) the involvement of the receptors pathways signaling through transcriptional activation. Because Bax is central in GBM apoptosis (Cartron et al., 2003b) , we investigated its implication in intracellular PGE 2 -induced apoptosis. Bax-expressing GBM cells (BeGBM) were microinjected with PGE 2 and then probed with a conformation-specific antibody (6A7 antibody) which recognizes only the active conformation of Bax , As shown in Figure 4d , the GBM cells microinjected with PGE 2 were labelled by the 6A7 antibody, suggesting that Bax was activated by the microinjection of PGE 2 . As a control we used PGD 2 and of Bax activation was not observed under these conditions (data not shown).
The intracellular PGE 2 -induced apoptosis is Bax-dependent The involvement of Bax in PGE 2 -induced apoptosis was first suggested by the fact that the overexpression of mPGES-1 in Bax-deficient GBM (BdGBM) primary cultures (Cartron et al., 2003b) did not affect the response of these cells to staurosporine-induced apoptosis (Figure 5a ). The microinjection of PGE 2 failed to induce cell death in these cells (Figure 5b ) but the ectopic expression of Bax (BdGBM-Bax), which restores the apoptotic sensitivity of these cells (Supplementary data 5), also reinstates cell death induced by PGE 2 microinjection (Figure 5b, closed bars) . The cellpermeant peptide BIP was shown by Sawada et al. (2003) to inhibit Bax translocation to the mitochondria and Bax-dependent apoptosis. The addition of BIP (200 mM, 1 h before microinjection) inhibits PGE 2 -induced apoptosis in BeGBM (Figure 5c ). Bcl2 is a cellular antiapoptotic protein and a functional antagonist of Bax (Cory and Adams, 2002) . BeGBM overexpressing Bcl2 (BeGBM-Bcl2) were efficiently protected from PGE 2 -induced apoptosis, even when very high concentrations of PGE 2 were injected (Figure 5d) . Similarly, the knockdown of Bax expression in BeGBM by SiRNA blocks the apoptogenic properties of micro-injected PGE 2 (data not shown).
PGE 2 directly induces an apoptotic change of conformation of Bax To identify further the molecular events underlying the Bax dependency of PGE 2 -induced apoptosis, we used isolated rat liver mitochondria incubated with IVT 35 S-radiolabeled Bax with increasing concentrations of PGE 2 . Bax does not spontaneously associate with mitochondria under these conditions unless it is activated by proapoptotic signals such as Bid (Cartron et al., 2004a) . The amount of mitochondria-associated Bax was analysed by PhosphorImager and quantified by the ImageJ software (see Materials and methods). As shown on the graph (Figure 6a ), PGE 2 induced Bax translocation and membrane insertion into the mitochondria in a dose-dependent way. Quite remarkably, PGE 2 led to the full integration of IVT Bax in the mitochondria as viewed by its resistance to alkaline treatment (Figure 6b ). On the other hand, no effects were observed with PGD 2 under these circumstances (Figure 6b ). The integration of Bax into mitochondria suggests that Bax undergoes an apoptotic-like change of conformation upon its incubation with PGE 2 . This contention was assessed by differential immunoprecipitation with the 2D2 and the 6A7 anti-Bax antibodies. As shown in Figure 6d , PGE 2 induced the recognition of Bax by the anti-conformational antibody 6A7. To determinate further the nature of PGE 2 /Bax interaction, recombinant Bax was incubated with acetylcholine esterase (AChE)-coupled PGE 2 or with an equivalent amount of AChE. After incubation, Bax was immunoprecipitated and AChE activity was measured in the immunoprecipitated fraction. Non-specific AChE activity (i.e. AChE not bound to PGE 2 co-immunoprecipitated with Bax) was subtracted to the values as shown in Supplementary data 6. PGE 2 was recovered in Baxassociated pellet in a dose-dependent way (Figure 6d) , suggesting a direct physical interaction between PGE 2 or PGE 2 -derived products and Bax.
Discussion
An increase in COX-2 activity represents a common mechanism in several types of neurotoxic insults involved in both acute and chronic neurological diseases through the synthesis of a wide variety of prostanoids, which exert multiple and sometimes contradictory functions through G protein-coupled receptors (Teismann et al., 2003; Hunot et al., 2004; Kawano et al., 2006; Herrmann et al., 2005) . COX-2-derived prostaglandins have potent inflammatory properties. Chronic inflammation condition is now considered as a risk factor in colon cancer, as well as in neurodegenerative and in cardiovascular diseases. However, in colon cancer cell lines, the elevated extracellular concentration of PGE 2 has been shown to modulate the expression of the antiapoptotic protein Bcl2 (Kawai et al., 2002) or to transactivate the EGFR and enhance AKT activity (Tessner et al., 2004) , which in both cases results in reduced Bax translocation to the mitochondria. On the other hand, COX-2 activity appears to be involved in the proapoptotic action of cannaboids derivatives both in brain and in colorectal tumors (Hinz et al., 2004; Patsos et al., 2005) and Bcl2 inhibits the PGE 2 -mediated apoptosis in B-cell lymphomas (Brown and Phipps, 1996) . The latter result suggests a complex role of COX-2 and PGE 2 in the control of tumoral cell survival. In this work, we have investigated the expression of the two major enzymes involved in the biosynthesis of PGE 2 in brain, COX-2 and mPGES-1, in GBM, the most aggressive form of gliomas. We found that the expression of COX-2 was homogenous in all the 60 GBM examined while on the other hand, these tumors could be divided into two distinct groups by the amount of mPGES-1 expressed: PGES H (high level) and PGES L (low level) (Figure 1) . Roughly, 32% of the GBM expressed a high amount of PGES and most tumoral cells were labelled by an antibody specific for the enzyme. The expression of mPGES-1 was found to be a significant predictor of survival in GBM patients (Figure 1c ). Quite remarkably, PGES H GBM exhibited high caspase-3 activities (Figure 1d ), suggesting that mPGES-1 was associated with an apoptotic phenotype. The latter contention was confirmed by studies with mPGES-1-transfected primary cultures in which both spontaneous and induced apoptosis were augmented ( Figure 2a ) and in vivo growth considerably reduced (Figure 2b) . Conversely, silencing mPGES-1 expression by shRNA decreased the threshold of apoptotic sensitivity of the primary cultures and increased their in vivo growth in the nude mice (Figure 2c and d) . The extinction of COX-2 by shRNA in the primary cultures had a strictly opposite effect, as apoptosis was augmented (Figure 2c ) and the growth in vivo considerably altered (data not shown). It is noteworthy that mPGES-1 is identical to a p53-induced gene (PIG12) which has been identified as being involved in p53 proapoptotic response through the control of the oxidative stress (Polyak et al., 1997; Jakobsson et al., 1999a) . Next, we have verified that the overexpression of (a) IVT radiolabelled Bax was incubated with isolated mitochondria and increasing amounts of PGE 2 . The amount of mitochondria-associated Bax was determined after SDS-PAGE of the mitochondrial pellet and analysis on PhosphorImager and quantification by ImageJ. The quantification graph was established from three independent experiments. (b) Experiments were similar to that described in a, but the insertion of Bax into mitochondrial membranes was assessed by an alkaline treatment (closed bars). Bax was similarly treated with PGD2 (open bars). (c) IVT-Bax was incubated with the indicated prostaglandins, then immunoprecipitated using the 6A7 and the 2D2 antibodies and Zysorbin G. IP( þ ), immunoprecipitation; IP(À), absence of immunoprecipitation. Triton-X 100 was added to induce artificially Bax activation and exposure of the 6A7 epitope. The resulting precipitates were analyzed by 12% SDS-PAGE and autoradiography. (d) Recombinant Bax was incubated with PGE 2 -AChE or with an equivalent amount of AChE before IP with an anti Bax antibody (Supplementary data 5) . Bax-associated PGE 2 was detected by the PGE 2 -specific AChEase activity in the immunoprecipitated fraction (see Materials and methods). The graph is representative of four independent experiments. *Po0.001; **P ¼ 0.002 mPGES-1 effectively led to an increase of PGE 2 synthesis (Figure 3a) . However, the addition of PGE 2 in the culture medium did not trigger apoptosis in the GBM primary cultures, ruling out the involvement of the EP receptors in the mPGES-1-induced apoptosis (Figure 3b) . By contrast, increasing the intracellular PGE 2 by pharmacological means (Figure3c and d) or by microinjection (Figure 4 ) increased apoptotic cell death in a Bax-dependent fashion ( Figure 5) . Interestingly, the closely related prostaglandin PGD 2 had no effects in the induction of apoptosis when microinjected under the same conditions as PGE 2 (Figure 5b ). We used a simplified system to analyse Bax-dependent apoptosis in which purified or in vitro synthesized Bax was incubated in the presence of isolated rat liver mitochondria (see, e.g., Cartron et al., 2004a) and its apoptoticlike membrane insertion analysed by centrifugation. The addition of PGE 2 to this system led to a dose-dependent membrane association/integration of Bax (Figure 6a and b), a feature also found when Bax was incubated with BH3-only proteins or by lowering pH, two allegedly Bax apoptotic activators (Cartron et al., 2004a, b) . As shown in Figure 6c and d, PGE 2 /Bax physical interaction caused a conformational change, shown by the immunoprecipitation by the 6A7 antibody, which recognizes an epitope normally hidden at the N terminus of the protein, whose exposure is usually associated with Bax insertion into mitochondrial membranes during apoptosis . Direct modulation of proteins activity by derivatives of PGH 2 , such as the cyclopentenone prostaglandins (i.e. 15-deoxy-D 12-14 PGJ 2 ; Perez-Sala et al., 2003) has been shown but our work is, to our knowledge, the first report of a proapoptotic intracellular PGE 2 target.
COX-2 expression has been associated with a poor prognosis in numerous types of cancers including colorectal tumors (Gupta and Dubois, 2001 ) and gliomas (Shono et al., 2001) and numerous results have suggested that the anti-apoptotic properties of COX-2 played an important role in tumor development (Gasparini et al., 2003; Gupta and Dubois, 2001) . However, our data show the existence of a new mechanism of activation of Bax through its physical interaction with PGE 2 . These findings raise the question of the relative importance of the balance between extracellular and intracellular PGE 2 in the control of apoptosis. The nature and the mechanism involved in the conformational change of Bax triggered by PGE 2 have to be further evaluated. However, our finding that PGE 2 can directly affect proteins involved in apoptosis could be important in the debate on the deleterious and/ or beneficial effects of inhibiting the production of prostanoids.
Materials and methods

Materials
Antibodies were purchased from indicated companies: COX-2 (Cayman, 160107), actin (Chemicon, MAB1501R, Chemicon International Ltd, Hampshire, UK), Bax 2D2 (amino acids 3-16, Sigma, B8554, Sigma-Aldrich, Lyon, France), Bax 6A7 (amino acids 12-24, Abcam, ab5714, Abcam, Paris, France), Bcl2 (Dako, M0887, Dako France SAS, Trappes, France), F 1 -ATPase (Molecular Probes, A-21350). mPGES-1 cDNA and polyclonal antibody directed against mPGES-1 were obtained as described earlier (Jakobsson et al., 1999b) .
35
S-Met (Amersham, France), labeled proteins were synthesized from cDNAs using the TNT-coupled transcription/translation system from Promega (France). 15-PGDH inhibitor (CAY10397) was purchased from Cayman (70130). BIP peptide was synthesized by Sigma Genosys (Lyon, France) (VPMLK, Sawada et al., 2003) . Unless mentioned, chemical products and reagents were obtained from Sigma (France).
Immunoblots were quantified using the ImageJ software (NIH, USA).
Every experiment was repeated at least three independent times.
Statistical analyses were performed using the GraphPad software (San Diego, CA, USA).
Patients
Patient data as well as records (diagnosis, age, sex, date of death) were used with confidentiality according to French laws and recommendations of the French National Committee of Ethic.
Tumor samples were collected from adult patients after surgical resection or biopsy at the Department of Neurosurgery of the Hospital of Nantes over the years 1996-2001. Brain tumors were examined by two expert pathologists and graded according to the WHO system, on the basis of tumor cell types, mitotic index, cytoplasmic abnormalities, endothelial cell proliferation and necrosis. Control tissue was obtained from normal brain tissue found at the periphery of the resected tumor, or from control tissue from patients operated for other pathologies at the Department of Neurosurgery.
Immunohistochemistry
The cellular expression of mPGES-1 was assessed by immunohistochemistry (IHC) using a specific antibody provided by Professor Jakobsson (Karolinska Institutet, Sweden) visualized by the avidin-biotin complex method. Cryosections of 6 mm were obtained with a LEICA CM 1900 cryostat, then air-dried and fixed in cold acetone for 10 min. After treatment with 0.03% H 2 O 2 in methanol to block endogenous peroxidase activity, the sections were incubated with 3% bovine serum albumin-phosphate buffered saline (BSA-PBS) for 15 mn before incubation with primary antibody diluted in 0.1% BSA-PBS. Incubation at 41C overnight was followed by incubating with the corresponding biotinylated antibody for 30 mn at room temperature before revelation by 3-amino-9-ethylcarbazole (AEC, Vector Laboratories, Burlingame, CA, USA). Sections incubated without a primary antibody were used as a negative control. All sections were counterstained in Mayer's hematoxylin.
Cell culture and transfections
Human BeGBM and BdGBM cells were obtained as described previously (Cartron et al., 2003b) . For overexpression experiments, transfections were performed using indicated cDNA subcloned into pDEST12.2 vector (Invitrogen). Plasmid DNA (5 mg) was introduced into 10 6 BdGBM or BeGBM cells by electroporation (GenePulser, Bio-Rad) using 200 V/cm and 250 mF.
For knockdown experiments, shRNA sequences were designed using Ambion's siRNA target finder software and were cloned into pSilencert 2.1-U6 hygro vector (Ambion). The sequences used were following: siPGES: 1 ¼ siRNA I.D. #15440, 2 ¼ siRNA I.D. #15446; siCOX-2: 1 ¼ sense strand GCCUUCUCUAACCUCUCCUtt, antisense strand AGGA GAGGUUAGAGAAGGCtt, 2 ¼ sense strand CCGAGGU GUAUGUAUGAGUtt, antisense strand ACUCAUACA UACACCUCGGtt . Control shRNA was provided by the manufacturer and was designed as a non-targeting shRNA. Plasmid DNA (10 mg) was introduced as described above.
The transfected cells were selected in a medium containing neomycin (250 mg/ml) or hygromycin B (100 mg/ml).
Tumor xenografts
For in vivo experiments, 5 Â 10 5 cells were injected subcutaneously into five male Swiss Nude mice (Charles River, France). Control cells containing a non-targeting shRNA (Ambion, Austin, TX, USA) were injected in the contralateral flank of each mouse. Tumor volume was measured twice a week.
Caspase activation assay Total cell lysates were carried out and protein concentrations were measured by the Bradford technique. DEVDase activity was measured using the fluorometric CaspACE Assay System (Promega) and normalized to the sample protein concentration as described previously (Juin et al., 1998) .
PGE 2 internalization experiments
BeGBM primocultures were plated the day before treatment. PGE 2 (10 mM) and actinomycin D (20 ng/ml) were added to the culture medium. After 10 min, CAY10397 (15 mM) and ketoprofen (1 mM; Reid et al., 2003) were added, and cells were treated for 18 h. Cell death was then assessed by trypan blue staining and normalized to the cell death induced by the inhibitors without extracellular PGE 2 addition.
Microinjection experiments
Microinjection was performed as described by Cartron et al. (2004a) . Prostaglandins were co-injected with a dextran coupled to a fluorochrome (Oregon Green, Molecular Probes). The percentage of fluorescent cells exhibiting morphological apoptotic features was evaluated every hour following PGE 2 microinjection using an inverted fluorescent microscope (DMIRE2, Leica France). When indicated, actinomycin D was added to the cell culture 30 mn before the injection (20 ng/ml).
Confocal analysis
For confocal analysis, the cells were fixed with 4% paraformaldehyde and 0.19% picric acid for 30 min at room temperature. After washing with PBS, the cells were permeabilized with 0.1% SDS-PBS for 10 min at room temperature (RT), then saturated by 5% gelatin-PBS for 15 min at RT. The cells were incubated with indicated antibodies for 1 h at RT in 1% gelatin-PBS. The secondary antibodies used were coupled to a fluorochrome (Alexa 568 or 633, Molecular Probes).
Images were collected on a Leica TCS NT microscope with a 63 Â 1.3 NA Fluotar objective (Leica, France).
Cell-free assay for Bax insertion Mitochondria were prepared from normal rat liver and the cell-free association of Bax with the mitochondria was performed as described previously (Cartron et al., 2004a) . 35 S-Met-labeled Bax (2 fmol), PGE 2 and isolated rat liver mitochondria (100 mg mitochondrial proteins) were incubated in a standard import buffer for 1 h at 301C. Mitochondria were pelleted and samples were separated by SDS-PAGE. Gels were fixed and dried, and 35 S-labeled Bax was detected on a PhosphorImager scanner.
PGE 2 -AChE Bax assay Full-length His-tagged human Bax was purified as described previously (Cartron et al., 2003a) . His 6 -Bax 100 ng was incubated with PGE 2 -AChE for 1 h at 301C in BSA-saturated tubes to avoid a specific interactions. Immuno precipitation (IP) was performed with anti-Bax 2D2 antibody coupled to Zysorbin G according to the manufacturer's instructions (ZYMED). Three additional washes with washing buffer were carried out before Ellman's AChE activity was determined on the IP pellet. Plates were read at 415 nm.
PGE 2 immunoassay
The amount of PGE 2 was measured in cells lysates and culture medium using the PGE 2 Biotrak EIA System (Amersham Biosciences) according to the manufacturer instructions. About 10 4 cells were plated in 96-well plates the day before. Plates were read at 450 nm. PGE 2 concentrations were normalized to the protein concentration of the samples.
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